The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Global dissemination of extensively drug‐resistant carbapenemase‐producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control
Open accessAbstract
The prevalence of carbapenem‐resistant Gram‐negative bacilli is on the rise worldwide, posing a major public health threat. Previously, this was mostly a problem in Pseudomonas and Acinetobacter, but during the last decade, carbapenem resistance has escalated in medically important species such as Klebsiella pneumoniae and Escherichia coli. In particular, the rising trend in E. coli is of concern, as this may lead to almost untreatable community‐acquired infections. Resistance is conferred by carbapenemases, which are beta‐lactamases that can breakdown essentially all beta‐lactams. Moreover, bacteria carrying these resistance determinants are often resistant to other treatment options, due to the frequent co‐acquisition of non‐beta‐lactam resistance genes located on the same mobile genetic elements. The detection of carbapenemase‐producing Enterobacteriaceae (CPE) is a challenge, because some carbapenemases produce relatively discrete levels of carbapenem resistance. Current clinical evidence for treatment guidance is limited and based on retrospective observational studies and case reports. Existing data support the use of combination therapy for treatment of severe infections caused by CPE. Combination regimens including colistin, carbapenems, tigecycline, aminoglycosides and fosfomycin have been used. Randomized controlled studies of combination regimens are ongoing and may help to determine the optimal therapy. Novel beta‐lactamase inhibitors may also have a role in future treatment of these infections. Strict infection control measures including isolation or cohort care of affected patients as well as contact tracing and active screening are needed to curb the spread of CPE. In this review, we provide a clinical perspective on the management of patients infected or colonized with CPE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70143-2 · Cited by 2,922
Self-citationGlobal Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110655 · Cited by 2,378
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Nordmann, P., Cuzon, G., & Naas, T. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70054-4 · Cited by 1,579
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,431
Overview of Nosocomial Infections Caused by Gram-Negative Bacilli
Weinstein, R. A., Gaynes, R., Edwards, J. R., & System, N. N. I. S. (2005) · Clinical Infectious Diseases · doi:10.1086/432803 · Cited by 1,404
Walsh, T. R., Weeks, J., Livermore, D. M., & Toleman, M. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70059-7 · Cited by 1,250
Weinstein, M. P., Towns, M. L., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Barth Reller, L. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,228
Cited by
Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance
Pitout, J. D. D., Nordmann, P., & Poirel, L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01019-15 · Cited by 852
Lee, C.-R., Lee, J. H., Park, K. S., Kim, Y. B., Jeong, B. C., & Lee, S. H. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00895 · Cited by 739
Diekema, D. J., Hsueh, P.-R., Mendes, R. E., Pfaller, M. A., Rolston, K. V., Sader, H. S., & Jones, R. N. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00355-19 · Cited by 645
Portsmouth, S., van Veenhuyzen, D., Echols, R., Machida, M., Ferreira, J. C. A., Ariyasu, M., Tenke, P., & Nagata, T. D. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30554-1 · Cited by 420
Carmeli, Y., Armstrong, J., Laud, P. J., Newell, P., Stone, G., Wardman, A., & Gasink, L. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30004-4 · Cited by 417
The rapid spread of carbapenem-resistant Enterobacteriaceae
Potter, R. F., D’Souza, A. W., & Dantas, G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.09.002 · Cited by 403
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0902-x · Cited by 371
Metadata
- Authors
- Tängdén, T., & Giske, C. G.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2015-01-27
- Volume
- 277
- Issue
- 5
- Pages
- 501-512
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2017352107
- Cited by
- 322
- References
- 50
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.